JP2005504522A - トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション - Google Patents

トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション Download PDF

Info

Publication number
JP2005504522A
JP2005504522A JP2003507063A JP2003507063A JP2005504522A JP 2005504522 A JP2005504522 A JP 2005504522A JP 2003507063 A JP2003507063 A JP 2003507063A JP 2003507063 A JP2003507063 A JP 2003507063A JP 2005504522 A JP2005504522 A JP 2005504522A
Authority
JP
Japan
Prior art keywords
acid
growth factor
compound
receptor
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003507063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504522A5 (OSRAM
Inventor
マーレイ，スーザン・エフ
ワイアット，ジャクリーン・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of JP2005504522A publication Critical patent/JP2005504522A/ja
Publication of JP2005504522A5 publication Critical patent/JP2005504522A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2003507063A 2001-06-21 2002-06-19 トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション Pending JP2005504522A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/888,361 US20030064944A1 (en) 2001-06-21 2001-06-21 Antisense modulation of transforming growth factor beta receptor II expression
PCT/US2002/019665 WO2003000656A2 (en) 2001-06-21 2002-06-19 Antisense modulation of transforming growth factor beta receptor ii expression

Publications (2)

Publication Number Publication Date
JP2005504522A true JP2005504522A (ja) 2005-02-17
JP2005504522A5 JP2005504522A5 (OSRAM) 2006-01-12

Family

ID=25393053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003507063A Pending JP2005504522A (ja) 2001-06-21 2002-06-19 トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション

Country Status (5)

Country Link
US (2) US20030064944A1 (OSRAM)
EP (1) EP1406915A4 (OSRAM)
JP (1) JP2005504522A (OSRAM)
AU (1) AU2002316318A1 (OSRAM)
WO (1) WO2003000656A2 (OSRAM)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533986A (ja) * 2000-05-04 2003-11-18 エイブイアイ バイオファーマ， インコーポレイテッド スプライス領域アンチセンス組成物および方法
JP2009545300A (ja) * 2006-08-04 2009-12-24 ペスクレ，チェザーレ ｍｉＲＮＡの使用及びｍｉＲＮＡを含む組成物
JP2012147790A (ja) * 2006-05-19 2012-08-09 Academisch Ziekenhuis Leiden エキソンスキッピングを誘発する為の手段及び方法
KR20170095230A (ko) * 2014-11-16 2017-08-22 뉴로비전 파마 게엠베하 Tgf-r 신호의 억제제로서의 안티센스-올리고뉴클레오티드
JP2020058368A (ja) * 2014-05-01 2020-04-16 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体ｂ因子発現を調節するための組成物及び方法
JPWO2019013141A1 (ja) * 2017-07-10 2020-05-07 国立大学法人大阪大学 Ｔｄｐ−４３の発現量を調節するアンチセンスオリゴヌクレオチド及びその用途
JPWO2019124297A1 (ja) * 2017-12-18 2021-01-07 正之 森 ブラッダー細胞形成制御作用剤、並びに、該作用剤を導入した植物体
JP2023503202A (ja) * 2020-02-12 2023-01-26 アソキュラ・ファーマシューティカルズ・スージョウ・カンパニー，リミテッド アンチセンスオリゴヌクレオチドおよびペンドレッド症候群を処置するためのそれらの使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
WO2005019422A2 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
NZ548926A (en) * 2004-02-09 2009-07-31 Regenion Gmbh Inhibitors of TGF-R signaling for treatment of CNS disorders
WO2008109546A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
JP5710977B2 (ja) * 2007-11-05 2015-04-30 バルティック テクノロジー デヴェロプメント，リミテッド 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用
EP2305292A4 (en) * 2008-08-01 2013-02-20 So Pharmaceutical Corp TRANSDERMAL IMMUNIZER OF S / O TYPE
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008011A (en) * 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533986A (ja) * 2000-05-04 2003-11-18 エイブイアイ バイオファーマ， インコーポレイテッド スプライス領域アンチセンス組成物および方法
JP2012147790A (ja) * 2006-05-19 2012-08-09 Academisch Ziekenhuis Leiden エキソンスキッピングを誘発する為の手段及び方法
JP2009545300A (ja) * 2006-08-04 2009-12-24 ペスクレ，チェザーレ ｍｉＲＮＡの使用及びｍｉＲＮＡを含む組成物
JP2020058368A (ja) * 2014-05-01 2020-04-16 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体ｂ因子発現を調節するための組成物及び方法
JP7001663B2 (ja) 2014-05-01 2022-02-04 アイオーニス ファーマシューティカルズ， インコーポレーテッド 補体ｂ因子発現を調節するための組成物及び方法
KR102310899B1 (ko) 2014-11-16 2021-10-12 뉴로비전 파마 게엠베하 Tgf-r 신호의 억제제로서의 안티센스-올리고뉴클레오티드
JP2021072841A (ja) * 2014-11-16 2021-05-13 ニューロビジョン ファーマ ゲーエムベーハー Ｔｇｆ−ｒシグナリング阻害剤としてのアンチセンス−オリゴヌクレオチド
JP2018501816A (ja) * 2014-11-16 2018-01-25 ニューロビジョン ファーマ ゲーエムベーハー Ｔｇｆ−ｒシグナリング阻害剤としてのアンチセンス−オリゴヌクレオチド
KR20170095230A (ko) * 2014-11-16 2017-08-22 뉴로비전 파마 게엠베하 Tgf-r 신호의 억제제로서의 안티센스-올리고뉴클레오티드
JPWO2019013141A1 (ja) * 2017-07-10 2020-05-07 国立大学法人大阪大学 Ｔｄｐ−４３の発現量を調節するアンチセンスオリゴヌクレオチド及びその用途
JP7307417B2 (ja) 2017-07-10 2023-07-12 国立大学法人大阪大学 Ｔｄｐ－４３の発現量を調節するアンチセンスオリゴヌクレオチド及びその用途
JPWO2019124297A1 (ja) * 2017-12-18 2021-01-07 正之 森 ブラッダー細胞形成制御作用剤、並びに、該作用剤を導入した植物体
JP7312703B2 (ja) 2017-12-18 2023-07-21 正之 森 ブラッダー細胞形成制御作用剤、並びに、該作用剤を導入した植物体
JP2023503202A (ja) * 2020-02-12 2023-01-26 アソキュラ・ファーマシューティカルズ・スージョウ・カンパニー，リミテッド アンチセンスオリゴヌクレオチドおよびペンドレッド症候群を処置するためのそれらの使用
JP7321614B2 (ja) 2020-02-12 2023-08-07 アソキュラ・ファーマシューティカルズ・スージョウ・カンパニー，リミテッド アンチセンスオリゴヌクレオチドおよびペンドレッド症候群を処置するためのそれらの使用

Also Published As

Publication number Publication date
AU2002316318A1 (en) 2003-01-08
EP1406915A4 (en) 2006-10-04
WO2003000656A3 (en) 2003-02-27
EP1406915A2 (en) 2004-04-14
WO2003000656A2 (en) 2003-01-03
US20030064944A1 (en) 2003-04-03
US20040147472A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
JP4397585B2 (ja) クラスタリン発現のアンチセンスモジュレーション
US8093224B2 (en) Antisense modulation of C-reactive protein expression
JP2004509619A (ja) Ｆｌｉｐ−ｃ発現のアンチセンスモジュレーション
US6440739B1 (en) Antisense modulation of glioma-associated oncogene-2 expression
JP2005504522A (ja) トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション
US6656732B1 (en) Antisense inhibition of src-c expression
US20030114401A1 (en) Antisense modulation of Ship-1 expression
WO2003105755A2 (en) Antisense modulation of vegf-c expression
WO2003088921A2 (en) Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
US20050074878A1 (en) Antisense modulation of ptpn2 expression
JP2005506066A (ja) インスリン様成長因子結合タンパク質５発現のアンチセンスモジュレーション
WO2003104458A1 (en) Antisense modulation of il-1 receptor-associated kinase-1 expression
US6387699B1 (en) Antisense inhibition of A20 expression
US6870046B2 (en) Antisense modulation of interferon gamma receptor 2 expression
WO2004005312A1 (en) Antisense modulation of ptprk expression
US6355482B1 (en) Antisense inhibition of integrin beta 4 binding protein expression
US6884787B2 (en) Antisense modulation of transforming growth factor-beta 3 expression
WO2004015126A2 (en) Antisense modulation of edg1 expression
WO2003053342A2 (en) Antisense modulation of cd81 expression
US20040142898A1 (en) Antisense modulation of HKR1 expression
WO2003106647A2 (en) Antisense modulation of junctional adhesion molecule 3 expression
US6492172B1 (en) Antisense modulation of GU protein expression
US20030144224A1 (en) Antisense modulation of B-cell associated protein expression
US20060160758A1 (en) Antisense modulation of CD40 ligand expression
US20040048818A1 (en) Antisense modulation of e2f transcription factor 2 expression

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061116